secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enveric Biosciences, Inc. (ENVB)
CIK:        0000890821
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001641172-25-010275
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enveric Biosciences Q1 net loss narrows to $2.2M; progresses EB-003 IND timeline
--------------------------------------------------------------------------------

- Net loss $2.2M in Q1 2025 vs $2.5M in Q1 2024; diluted loss per share $1.22 vs $9.21.
- Cash and equivalents $4.3M at March 31, 2025, after closing $5M public offering.
- New U.S. patent for EVM401 Series (mescaline derivatives) and EB-003 IP expanded.
- Signed two licensing agreements for cannabinoid-COX-2 conjugates with Restoration Biologics.
- Targeting FDA IND submission for EB-003 by end of Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/890821/000164117225010275/0001641172-25-010275-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/890821/000164117225010275/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-010275

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer